R-Ras Inhibits VEGF-Induced p38MAPK Activation and HSP27 Phosphorylation in Endothelial Cells

Junko Sawada Fangfei Li Masanobu Komatsu

Cardiovascular Metabolism Program and Tumor Microenvironment and Cancer Immunology Program,
Sanford-Burnham-Prebys Medical Discovery Institute at Lake Nona, Orlando, Fla., USA

Key Words

Angiogenesis · Endothelial cells · VEGF signaling · R-Ras

Abstract

R-Ras is a Ras family small GTPase that is highly expressed in mature functional blood vessels in normal tissues. It inhibits pathological angiogenesis and promotes vessel maturation and stabilization. Previous studies suggest that R-Ras affects cellular signaling in endothelial cells, pericytes and smooth-muscle cells to regulate vessel formation and remodeling in adult tissues. R-Ras suppresses VEGF-induced endothelial permeability and vessel sprouting while promoting normalization of pathologically developing vessels in mice. It attenuates VEGF receptor-2 (VEGFR2) activation by inhibiting internalization of the receptor upon VEGF ligand binding, leading to significant reduction of VEGFR2 autophosphorylation. Here, we show that R-Ras strongly suppresses the VEGF-dependent activation of stress-activated protein kinase-2/p38 mitogen-activated protein kinase (SAPK2/p38MAPK) and the phosphorylation of downstream heat-shock protein 27 (HSP27), a regulator of actin cytoskeleton organization, in endothelial cells. The suppression of p38MAPK activation and HSP27 phosphorylation by R-Ras concurred with altered actin cytoskeleton architecture, re-

duced membrane protrusion and inhibition of endothelial cell migration toward VEGF. Silencing of endogenous R-Ras by RNA interference increased membrane protrusion and cell migration stimulated by VEGF, and these effects were offset by p38MAPK inhibitor SB203580. These results suggest that R-Ras regulates angiogenic activities of endothelial cells in part via inhibition of the p38MAPK-HSP27 axis of VEGF signaling.

© 2016 S. Karger AG, Basel

Introduction

VEGF plays multiple important roles in development and maintenance of blood vessels. It is a potent mitogen for endothelial cells (ECs) and also promotes migration and survival of these cells [1]. VEGF-A disrupts endothelial barrier function and strongly increases vessel permeability [2, 3]. A chronically elevated level of VEGF in tissues causes abnormal angiogenesis and vessel leakiness. One of the 3 VEGF receptors, VEGFR2, is the key mediator of VEGF signaling in vascular endothelium. The activation of VEGFR2 by VEGF results in tyrosine phosphorylation of VEGFR2, triggering transduction of downstream signaling pathways. The p38 mitogen-activat-

ed protein kinase/heat-shock protein 27 (p38MAPK-HSP27) signaling, downstream of VEGFR2 Tyr1214 phosphorylation, leads to actin cytoskeleton reorganization and the migration of ECs to drive the angiogenic sprouting of ECs. While VEGF signaling potently induces the sprouting and elongation of new vessels, the formation of functional vessels requires additional cellular signaling to promote vessel maturation. The vessel sprouting and maturation processes must be precisely regulated by balancing pro- and antiangiogenic signals [4, 5]. The imbalanced signals due to excessive VEGF stimuli leads to overproduction of immature and defective vessels with chaotic organization, as seen in pathological angiogenesis in tumors and diabetic retinopathy [6, 7]. In peripheral arterial disease, imbalanced angiogenesis appears to be a crucial reason for the failure of clinical trials for VEGF gene therapy that were conducted in attempts to reperfuse ischemic tissues with VEGF-induced new vessels [8–10].

The small GTPase, R-Ras, plays an important role in attenuating the response of ECs to VEGF and inhibiting pathological angiogenesis [11]. Using mouse genetic models, we previously demonstrated that R-Ras inhibits excessive vessel sprouting [12] while promoting the maturation of nascent vessels in mouse tumors [11]. The R-Ras deficiency increased tumor vessel density but exaggerated the deformation and functional abnormalities of tumor vessels. On the other hand, gain-of-function of R-Ras normalized the vessel structure and function in VEGF-induced angiogenesis in Matrigel implants. R-Ras is highly expressed in differentiated vascular smooth-muscle cells, ECs and pericytes of mature blood vessels in normal adult tissues [11, 12]. In contrast, R-Ras is strongly downregulated during proliferative regeneration and remodeling of blood vessels [12]. R-Ras can activate PI3-kinase, and, through it, Akt [13]. However, unlike closely related Ras proteins such as K-Ras and H-Ras, R-Ras does not activate the Raf-MAP kinase pathway or transform rat fibroblasts [13, 14]. R-Ras enhances integrin adhesion to the extracellular matrix [11, 15] and also enhances endothelial barrier function by stabilizing VE-cadherin in adherens junction [11]. Genetic studies in mice demonstrated that R-Ras inhibits vascular cell proliferation and invasion, and promotes vascular quiescence displaying its activity to counterbalance vessel activation and promote the normalization of pathologically regenerating blood vessels [11, 12]. The vascular normalization effect of R-Ras appears to be independent of hypoxia sensing via PHD2/HIF-2 pathway [11, 16]. The mechanism of R-Ras-mediated blood vessel regulation is incompletely understood.

R-Ras is a Ras protein that negatively regulates angiogenic endothelial sprouting, and hence, it is functionally contrasting to other closely related Ras homologs such as H-Ras and Rap1, which positively regulate this process [17–20]. The unique effect of R-Ras on vessel regulation may be at least in part due to its ability to attenuate VEGF signaling in ECs. We have previously showed that R-Ras inhibits clathrin-dependent internalization of VEGFR2 upon VEGF stimulation that is required for the full activation of the receptor [21]. This effect leads to significant downregulation of receptor autophosphorylation at tyrosine phosphorylation sites including the Tyr1214 residue. In this study, we focused on the effect of R-Ras on the p38MAPK-HSP27 signaling downstream of VEGFR2 Tyr1214 phosphorylation and investigated how R-Ras affects actin reorganization, membrane dynamics and motility of ECs regulated by this VEGF pathway.

Methods

Antibodies and Reagents

Antibodies for the following proteins were purchased from Cell Signaling Technology, Inc. (Danvers, Mass., USA): p38MAPK, phospho-p38MAPK Thr180/Tyr182, HSP27, phospho-HSP27 Ser15 and phospho-HSP Ser78. Anti-phospho-VEGFR2 Tyr1214 was purchased from EMD Millipore (Billerica, Mass., USA). Antibodies for R-Ras were obtained from Cell Signaling Technology or Abcam (Cambridge, Mass., USA). Alexa Fluor® 594 phalloidin was purchased from Life Technologies (Carlsbad, Calif., USA). Recombinant human VEGF-A₁₆₅ was purchased from R&D Systems (Minneapolis, Minn., USA).

Cell Culture, Lentivirus Transduction and siRNA Transfection

Human umbilical cord vein endothelial cells and growth media EGM-2 were purchased from Lonza (Basel, Switzerland). Cells were transduced with a constitutively active form of R-Ras (R-Ras38V), or insertless control using pLenti6 lentivirus expression vector (Invitrogen) as described before [12]. R-Ras knockdown was carried out by lentivirus transduction of shRNA that targets the R-Ras sequence 5'-GGA AAT ACC AGG AAC AAG A-3' as described previously [11]. The negative control (NC) shRNA, which does not target any known sequence of the human, mouse, rat or zebrafish origin, was obtained from COSMO BIO Co., Ltd (Tokyo, Japan) [11]. To evaluate the stimulation of VEGF, cells were starved for growth factors overnight with 2% horse serum in EBM-2 basal media, stimulated with VEGF, and lysed in cell lysis buffer (0.5% SDS phosphate buffer, pH 7.4) at various time points for Western blot analyses. For the treatment of p38MAPK inhibitor, growth factor-starved cells were incubated with or without 10 nM SB203580 for 2 h and stimulated with 50 ng/ml VEGF. For actin filament staining, cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton-X/PBS and stained with Alexa Fluor 594 phalloidin.

Fig. 1. R-Ras reduces VEGF-dependent phosphorylation of p38MAPK. **a** Time course analysis of p38MAPK activation. The constitutively active form of R-Ras, R-Ras38V or control empty vector (mock) was transduced in endothelial cells. Cells were starved for serum and growth factors overnight, and stimulated with 50 ng/ml VEGF. Cell lysate was collected at various time points to determine the phosphorylation of p38MAPK (Thr180/Tyr182) and VEGFR2 (Tyr1214) as well as the total levels of these proteins by Western blotting. **b** The level of phospho-p38MAPK (Thr180/Tyr182) was quantified from the Western blot at each time point, normalized to total p38MAPK, and presented as relative values compared with the mock-transduced control cells at 10 min. A representative result from three independent experiments is shown. **c** Cells were stimulated with 50 ng/ml VEGF for 15 min, and cell lysate was analyzed for phosphorylation of p38MAPK. The graph shows one set of the representative data from 3 independent experiments. n.s. = Nonsignificant difference; p-p38MAPK = phosphorylated p38MAPK. Error bars, SEM, n = 3, ** p < 0.01, *** p < 0.001.

Immunofluorescence Staining of Tumor Vessels

R-Ras knockout (KO) mice have been described previously [12]. All animal experiments were performed in accordance with protocols approved by the institutional Animal Care and Use Committee of the Sanford-Burnham-Prebys Medical Discovery Institute. B16F10 melanoma and Lewis lung carcinoma (LLC) cells (1×10^6 cells) were subcutaneously injected into the flank of R-Ras KO or wild-type (WT) control mice [11]. Ten (B16F10) or 14 days (LLC) later, tumors were collected. Histological frozen sections were stained with anti phospho-HSP27 Ser78 and CD31 antibodies, and imaged using a Nikon Eclipse 90i microscope. The area of phospho-HSP27 and CD31 double-positive staining was quantified and normalized to total CD31 area to analyze the phosphorylation of HSP27 in the tumor vessels. Two animals were used for each group. The total number of vessels analyzed for B16F10 tumors was 258 (WT) and 442 (KO) and 1,239 (WT) and 1,774 (KO) vessels were analyzed for LLC tumors.

Cell Projection and Retraction Measurement

Cells were fluorescently labeled with CellTracker™ Green CMFDA (Life Technologies), and plated on Nunc™ Lab-Tek™ II Chamber Slide™ (Nalge Nunc International, Penfield, N.Y., USA). After overnight starvation for growth factors, a live image was captured by Nikon Eclipse Ti (Nikon Instrument Inc.) equipped with a Coolsnap HQ2 14bit CCD camera (Photomet-

rics) with or without stimulation by 50 ng/ml VEGF-A. For the inhibition of p38MAPK, cells were treated with 10 nM SB203580 (Cell Signaling Technology) for 2 h before VEGF stimulation. The cell projection and retraction activities were determined by time-lapse microscopy for the changes of the cell shape between 10 and 15 min post-VEGF stimulation. The areas of projecting or retracting cell membrane were determined by NIS-Elements (Nikon Instrument Co.).

Cell Migration Assay

Cells were starved for serum in EBM-2 media (Lonza) for 8 h. Cells were then seeded onto the upper compartment of an 8- μ m Transwell chamber (Corning) and cultured for 1.5 h to let the cells adhere. VEGF-A (5 ng/ml) was added into the lower compartment, and the cells were further incubated for 2 h. The upper surface of the Transwell membrane was scraped by cotton swab to remove nonmigrated cells. After fixing with 4% paraformaldehyde, migrated cells on the lower surface were stained with crystal violet and quantified by counting. The average counting of triplicated chambers is presented.

Statistics

Statistics were performed using 1-way ANOVA with Bonferroni's multiple comparison test. Student's t test was used for tumor vessel analyses. Error bars represent SEM.

Fig. 2. R-Ras silencing enhances p38MAPK phosphorylation induced by VEGF. **a** Endogenous R-Ras was knocked down by R-Ras shRNA. Cells were stimulated with VEGF at the indicated doses for 15 min. **b** Cells were stimulated with or without 50 ng/ml VEGF. The level of phospho-p38MAPK was quantified, normalized to total p38MAPK, and presented as relative values compared with the VEGF-stimulated control cells. n.s. = Nonsignificant difference; p-p38MAPK = phosphorylated p38MAPK. Error bars, SEM, n = 3, * p < 0.05.

Results

R-Ras Attenuates p38MAPK Activation Induced by VEGF

The activation of VEGFR2 by VEGF results in tyrosine phosphorylation of VEGFR2, triggering the transduction of downstream signaling pathways. The p38MAPK-HSP27 signaling downstream of VEGFR2 Tyr1214 phosphorylation leads to actin cytoskeleton reorganization, cell membrane spreading and the migration of ECs. R-Ras significantly reduces VEGFR2 phosphorylation through the inhibition of clathrin-mediated internaliza-

tion of the receptor [21]. We investigated the effect of R-Ras on p38MAPK activation by VEGF. Cultured ECs were transduced with constitutively active mutant of R-Ras (R-Ras38V) or insertless vector (mock) control. These cells were stimulated with VEGF following overnight culture in low-serum-containing media. The expression of R-Ras38V inhibited the phosphorylation of VEGFR2 at Tyr1214, as we have reported previously (fig. 1a) [21]. VEGF strongly increased the phosphorylation of p38MAPK (Thr180/Tyr182) in the mock control ECs, with the peak activation at 15 min post-VEGF stimulation (fig. 1a–c). In contrast, we observed a strong reduction of p38MAPK phosphorylation in the ECs expressing R-Ras38V, demonstrating a significant inhibitory effect of R-Ras on the p38MAPK activity downstream of VEGFR2. R-Ras does not seem to have a direct effect on VEGF-independent p38MAPK activity, as we did not observe obvious difference between the mock and R-Ras38V-transduced ECs for the basal levels of p38MAPK phosphorylation without VEGF stimulation. In addition, R-Ras did not have an effect on the total expression level of p38MAPK (fig. 1a).

To further investigate the effect of R-Ras, we knocked down endogenous R-Ras by shRNA and stimulated ECs with VEGF. R-Ras knockdown enhanced phosphorylation of p38MAPK (fig. 2a, b), demonstrating the role of R-Ras in negatively regulating the VEGF-p38MAPK signaling.

R-Ras Attenuates VEGF-Dependent HSP27 Phosphorylation

HSP27 is a molecular chaperone and an actin cytoskeleton modulator implicated in cancer progression [22]. In ECs, HSP27 is downstream of the VEGFR2-p38MAPK pathway and is phosphorylated by MAPK-activated protein kinase 2 (MK2) [23]. HSP27 is expressed in ECs and is an essential mediator of actin reorganization induced by VEGF [24]. Since we observed a strong attenuation of VEGF-dependent p38MAPK activity by R-Ras, we examined the effect of R-Ras on HSP27 by analyzing its phosphorylation at 2 serine sites, the Ser15 and Ser78 residues (fig. 3a, b). VEGF increased phosphorylation of both serine sites of HSP27 in mock control cells. The phosphorylation at Ser78 was particularly robust. The expression of R-Ras38V reduced the phosphorylation of Ser15 by approximately 40% and Ser78 by 70% in VEGF-stimulated ECs. Thus, R-Ras38V nearly nullified the VEGF-dependent phosphorylation of HSP27 at Ser15 to the unstimulated basal level, and also substantially reduced the phosphorylation at Ser78.

Fig. 3. R-Ras regulates VEGF-dependent phosphorylation of HSP27. **a** Western blot analysis of HSP27 phosphorylation. ECs were stimulated with 50 ng/ml VEGF for 15 min. The phosphorylation at Ser15 (pS15) and Ser78 (pS78) of HSP27 were analyzed by Western blot using phospho-specific antibodies. **b** The level of phosphorylation was quantified and normalized to the total HSP27. The fold differences were presented in relative values with control mock cells with VEGF stimulation. **c** R-Ras knockdown enhances phosphorylation of HSP27. n.s. = Nonsignificant difference. Error bars, SEM, $n = 3$, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

Similar to the observation in the analysis of p38MAPK (fig. 1a–c), R-Ras did not seem to show a direct effect on the VEGF-independent HSP27 phosphorylation, as we did not observe significant differences between mock and R-Ras38V-transduced ECs in the basal levels of HSP27 phosphorylation before VEGF stimulation (fig. 3a, b). We also observed that R-Ras did not have an

effect on the total expression level of HSP27 (fig. 3a). The shRNA-mediated knockdown of endogenous R-Ras significantly enhanced phosphorylation of both serine residues upon VEGF stimulation of ECs, but not before VEGF stimulation (fig. 3c), further demonstrating the role of R-Ras in suppressing HSP27 phosphorylation induced by VEGF. These results are in agreement with

Fig. 4. Genetic ablation of R-Ras increases phosphorylation of HSP27 in the tumor endothelium. B16F10 melanoma (**a**) or LLC (**b**) tumors were grown for 10 or 14 days, respectively, in R-Ras KO or WT control mice. The tumor endothelium was analyzed for HSP27 phosphorylation by co-immunostaining of tumor sections with anti-CD31 and phospho-HSP27 Ser78 antibodies followed by microscopy. Scale bar: 100 μ m. **c** Quantification of HSP27 Ser78 phosphorylation. The area of phospho-HSP27⁺CD31⁺ double staining was quantified and normalized to total CD31 area to analyze phosphorylation of HSP27 in the tumor vessels. The tumor vascularity in each group was determined by the total CD31 area and vessel density in tumor sections. Data are presented as fold increase relative to the WT control animals. There were 2 animals per group. The total number of vessels analyzed for B16F10 tumors was 258 (WT) and 442 (KO), and the total number analyzed for LLC tumors was 1,239 (WT) and 1,774 (KO). Error bars, SEM, * $p < 0.05$, *** $p < 0.001$.

the effect of R-Ras on VEGFR2 and p38MAPK activation upstream of HSP27 (fig. 1, 2).

We next investigated the role of R-Ras in regulating HSP27 phosphorylation *in vivo*. B16F10 melanoma or LLC cells were subcutaneously transplanted to WT or R-Ras KO mice, and tumor vessels were analyzed by immunostaining tumor sections for CD31 and phospho-HSP27 Ser78. We have previously shown that R-Ras KO mice exhibit enhanced angiogenesis and chaotic vascular structure in these tumor models [11, 12]. In this study, the phosphorylation of HSP27 was found elevated in the ECs of tumor vessels developing in R-Ras KO mice compared with those in WT control mice; it correlated with increased tumor vascularity in the R-Ras KO mice (fig. 4). This observation is consistent with the elevated phosphorylation of VEGFR2 at Tyr1214 observed in the tumor endothelium of R-Ras KO mice [21] as well as the inhibitory effect of R-Ras on HSP27 phosphorylation observed in cultured ECs (fig. 3a–c). Taken together, these observations suggest a significant effect of R-Ras on the VEGF-HSP27 pathway in pathologically regenerating blood vessels.

R-Ras Alters Reorganization of Actin Cytoskeleton Induced by VEGF

Phosphorylation of HSP27 modifies the interaction of HSP27 with actin and facilitates actin polymerization [25–27]. VEGF strongly induces reorganization of actin cytoskeleton structures in ECs, in which HSP27 phosphorylation downstream of VEGFR2-p38MAPK signaling plays a major role [28–30]. To examine the effect of R-Ras on the VEGF-induced actin cytoskeleton reorganization, cells were stimulated with VEGF and stained with phalloidin to visualize actin filaments. Unstimulated mock-transduced control cells exhibited actin filaments localized mainly at the cell periphery in a confluent EC culture (fig. 5a). The subconfluent culture was only weakly stained with phalloidin (fig. 5b). As previously reported [31], the stimulation of ECs with VEGF strongly induced the formation of tight bundles of actin filaments that constitute stress fibers running across the cytoplasm in confluent and subconfluent cultures (fig. 5a–c). These stress fibers were assembled in irregular thickness. In contrast, thinner but well-defined stress fibers were found accumulated along the membrane periphery of unstimulated R-Ras38V-transduced cells. Long, thin stress fibers were also observed across the cytoplasm of these cells. These stress fibers were oriented in parallel to each other in a well-organized fashion. Such an orientation of actin fibers was

independent on VEGF but dependent on R-Ras activity, as it was found before VEGF stimulation in R-Ras38V-transduced cells but not in the mock-transduced control cells (fig. 5a–c) or R-Ras-silenced cells (data not shown). VEGF enhanced transcytoplasmic stress fibers in R-Ras38V-expressing ECs in both confluent and subconfluent cultures. However, these stress fibers did not form thick bundles and remained relatively thin, with a uniform thickness, in contrast to the bundles of stress fibers with irregular length and thickness found in the control cells upon VEGF stimulation. The stress fibers in R-Ras38V-expressing cells are evenly positioned in parallel with a constant distance between the fibers. In the confluent culture, this positional arrangement of the stress fibers continues with the stress fibers formed in adjacent cells, producing the orderly architecture of the actin network in a sheet of EC monolayer (fig. 5a). Interestingly, a similar parallel pattern of actin cytoskeleton organization is found in confluent ECs under laminar shear stress [32].

We next treated ECs with a specific inhibitor of p38MAPK, SB203580, to examine whether direct inhibition of p38MAPK produces a similar effect to the effect of R-Ras38V on the actin cytoskeleton in VEGF-treated ECs. The control and R-Ras-silenced ECs treated with SB203580 both exhibited the loss of thick bundles of transcytoplasmic stress fibers induced by VEGF (fig. 5d). However, SB203580 did not produce an effect like that of R-Ras38V to induce the orderly organization of parallel stress fibers (fig. 5a–c). This observation indicates that the effect of R-Ras on actin cytoskeleton architecture is not solely due to the inhibition of VEGF-induced p38MAPK activation and its downstream actin polymerization, although this effect on p38MAPK may still be important for controlling the characteristics of stress fibers and other actin structures to be assembled in ECs.

R-Ras Attenuates Membrane Dynamics Induced by VEGF

We next investigated the effect of R-Ras on cell membrane dynamics stimulated by VEGF. VEGF induces actin reorganization facilitating lamellipodia formation and plasma membrane protrusion necessary for propelling and guiding the migration of ECs [31, 33]. Activation of p38MAPK has been known to enhance lamellipodia and migration of ECs in a HSP27-dependent manner [28, 34]. In our study, VEGF enhanced the formation of lamellipodia in the subconfluent culture of control cells as expected (fig. 5c, arrowheads). In contrast, the formation of

Fig. 5. R-Ras influences actin cytoskeleton organization. Cells were starved for growth factors overnight and stimulated with or without 50 ng/ml VEGF for 30 min. Confluent monolayer culture (**a**, **d**) and subconfluent cultures (**b**, **c**) were fixed and stained with Alexa Fluor 594 phalloidin (green). The boxed areas in **b** are magnified in **c**. **c** Fluorescence intensity was equally enhanced in the left panels in both pictures (VEGF-, mock and R-Ras38V) in order

to better visualize the actin filaments in unstimulated cells. Next, endogenous R-Ras was silenced by shRNA, and growth factor-starved cells were treated with SB 203580 for 2 h. Cells were then stimulated with 50 ng/ml VEGF for 30 min and stained with phalloidin (**d**). The experiment was repeated at least 3 times. Representative images were shown. Scale bar: 50 μ m.

Fig. 6. R-Ras silencing enhances VEGF-induced cell membrane projection. **a** ECs transduced with shRNA for R-Ras or NC shRNA were treated with or without 10 nM of the p38MAPK inhibitor SB203580 for 2 h. Cells were then stimulated with 50 ng/ml VEGF and observed by time-lapse microscopy for changes in cell shape

between 10 and 15 min post-VEGF stimulation (indicated by arrows). **b** Cell shape changes with the areas of projecting (red) and retracting (blue) cell membrane are indicated. **c** The fraction of projecting (red) and retracting (blue) membrane area versus total cell area (% area change) was determined. ** $p < 0.01$, *** $p < 0.001$.

lamellipodia was significantly diminished in the subconfluent culture of R-Ras38V-expressing ECs treated with VEGF, indicating that R-Ras inhibits VEGF-dependent lamellipodia formation (fig. 5c). It has been shown that inhibition of endogenous R-Ras in ECs by dominant negative R-Ras significantly enhances the dynamic changes of cell shape in growth factor-rich media [11]. Therefore, we next analyzed how R-Ras affects the effect of VEGF on membrane extension, and examined whether this is a p38MAPK-mediated effect. For this purpose, we con-

ducted time-lapse microscopy in which endogenous R-Ras is silenced in ECs by shRNA transduction, and analyzed the cell membrane dynamics with or without SB203580 (fig. 6). Consistent with the role of VEGF in promoting actin polymerization, VEGF increased membrane extension at the edge of the mock-transduced control cells (fig. 6a–c). R-Ras silencing significantly increased the VEGF-dependent membrane extension (fig. 6c). The fraction of retracting membrane area was reduced because the cell membrane was mostly extending

Fig. 7. R-Ras inhibits directional EC migration toward VEGF. **a** R-Ras38V-transduced and control ECs were starved for growth factors for 8 h and placed into the upper compartment of a Transwell chamber. VEGF (5 ng/ml) was added into the lower compartment and incubated for 2 h. Migration of ECs toward VEGF was quantified. $n = 5$, *** $p < 0.001$. **b** R-Ras-silenced ECs were starved for growth factors for 8 h. Cells were treated with 10 nM SB203580 for 2 h before migration assay. n.s. = Nonsignificant difference. $n = 5$, * $p < 0.05$.

in the first 10–15 min of VEGF stimulation. The treatment of cells with SB203580 abolished VEGF-dependent membrane protrusion activity to a similar level in the control and R-Ras-silenced ECs, demonstrating that p38MAPK inhibition offsets the effect of R-Ras silencing (fig. 6c). Based on these results, we conclude that the activity of p38MAPK was responsible for the enhanced membrane extension caused by the R-Ras deficiency. These observations demonstrate that endogenous R-Ras attenuates EC membrane dynamics upon VEGF stimulation via downregulation of VEGF-dependent p38MAPK activity. This observation is consistent with the effect of R-Ras on VEGFR2 Tyr1214 phosphorylation upstream of p38MAPK.

R-Ras Inhibits Migration of ECs toward VEGF

Lamellipodia extension and membrane protrusion driven by actin polymerization are essential to cell migration [31]. Since we observed the effect of R-Ras on VEGF-induced membrane dynamics, we next analyzed how R-Ras affects directional migration of ECs toward VEGF, by means of a culture-insert system. The expression of R-Ras38V blocked EC migration toward VEGF (fig. 7a). On the other hand, R-Ras silencing increased EC migration toward VEGF (fig. 7b). These results are in agreement with the effect of R-Ras that strongly attenuates VEGFR2

Tyr1214 phosphorylation, p38MAPK activation and HSP27 phosphorylation (fig. 1–3) that are necessary for VEGF to promote EC migration.

The inhibition of p38MAPK by SB203580 reduced the migration of control ECs by 60% underscoring the importance of p38MAPK for VEGF-induced EC migration (fig. 7b). SB203580 reduced the migration of R-Ras-silenced cells to the same level as the SB203580-treated control cells without R-Ras silencing. Thus, the 2 cell types with different R-Ras expression levels did not exhibit any difference in migration activity upon p38MAPK inhibition. This result, combined with the strong inhibitory effect of R-Ras on VEGF-p38MAPK signaling (fig. 1–3), suggests that R-Ras inhibits EC migration via downregulation of p38MAPK activation by VEGF.

Discussion

Previous studies have shown the importance of R-Ras for negatively regulating the effect of VEGF on angiogenesis. For instance, R-Ras inhibits tumor angiogenesis and VEGF-dependent neovascularization in Matrigel implants in mice [11, 12]. Consistent with this in vivo role, R-Ras has been shown to inhibit internalization of VEGFR2 upon VEGF stimulation, thereby attenuating the activation and autophosphorylation of the receptor [21]. In this study, we investigated how this R-Ras activity impacts the VEGF signaling and EC activities, with a particular focus on the events downstream of VEGFR2 Tyr1214 phosphorylation. We showed that R-Ras strongly downregulates p38MAPK activation and its downstream HSP27 phosphorylation, concomitantly with the reduction of VEGFR2 Tyr1214 phosphorylation. It has been well-documented that the VEGFR2-p38MAPK-HSP27 pathway is crucial for mediating the effect of VEGF on actin stress fiber assembly, lamellipodia formation and the migration of ECs [24, 28, 31]. The inhibition of this pathway by R-Ras was associated with a distinct pattern of actin cytoskeleton architecture, reduced lamellipodia formation and reduced membrane protrusion in VEGF-stimulated ECs. In addition, the directional migration of ECs toward VEGF was blocked by constitutively activated R-Ras and enhanced by silencing of endogenous R-Ras. The inhibition of p38MAPK by SB203580 offset the membrane protrusion and migration activities enhanced by R-Ras silencing. R-Ras38V did not affect the basal levels of p38MAPK and HSP27 phosphorylation before VEGF stimulation. Likewise, R-

Ras silencing had little effect on the p38MAPK and HSP27 phosphorylation levels before VEGF stimulation. These results demonstrate that the effects of R-Ras on p38MAPK and HSP27 are attributable to the inhibition of the VEGF signaling. MAPKAPK-2 forms a molecular complex with p38MAPK and HSP27 [35], and it mediates VEGFR2-p38MAPK signaling [36]. The p38MAPK inhibitor we used in this study, SB203580, suppresses the activation of MAPKAPK-2 by p38MAPK and subsequent phosphorylation of HSP27 [37]. Based on these observations, we conclude that R-Ras inhibits the induction of membrane protrusion and migration by VEGF mainly by downregulating the VEGFR2-p38MAPK-HSP27 axis of VEGF signaling. This finding suggests a mechanism by which R-Ras promotes the quiescence of ECs and attenuates vessel sprouting to prevent excessive angiogenesis. Supporting the relevance of our findings to angiogenesis, we found elevated HSP27 phosphorylation in the endothelium of tumor vasculature formed in R-Ras KO mice, which exhibited exaggerated and defective tumor angiogenesis and VEGF-induced angiogenesis [11, 12].

The phalloidin staining of ECs revealed that R-Ras has a profound influence on actin cytoskeleton architecture before and after VEGF stimulation. It is conceivable that, in VEGF-stimulated cells, R-Ras negatively regulates actin polymerization and stress fiber assembly through its inhibitory effect on the p38MAPK axis of VEGF signaling. However, ECs expressing constitutively active R-Ras do show enhanced stress fibers upon VEGF stimulation, albeit the structure of these actin fibers is quite distinct from that of WT ECs. It should be noted that the expression of activated R-Ras did not abolish p38MAPK activation by VEGF. Rather, it strongly attenuated p38MAPK activation, with a 13-fold increase in Thr180/Tyr182 phosphorylation in R-Ras38V-transduced cells compared with a 30-fold increase in the mock-transduced control cells. The cells expressing activated R-Ras exhibited well-organized, uniform and parallel stress fibers. Interestingly, the formation of these stress fibers did not support cell migration. It may have even inhibited migration as cell migration was blocked concomitantly with the formation of such actin structures. The formation of this type of stress fibers could not be reproduced in the control WT cells by direct inhibition of p38MAPK using a chemical inhibitor. These observations suggest that there are additional mechanism(s) underlying the regulation of endothelial actin cytoskeleton architecture by R-Ras. The role of R-Ras in integrin adhesion is well established [15]. Integrin focal adhesion anchors the actin

cytoskeleton to the extracellular matrix and regulates the assembly and organization of actin stress fibers [38]. It is likely that integrin focal adhesion contributes to the actin network organization by R-Ras. The significance of the integrin-dependent R-Ras effect should be investigated in additional studies. Of note, similarly to what we observed in the confluent R-Ras-transduced ECs under VEGF stimulation, the confluent ECs under laminar shear stress are known to develop well-organized stress fiber alignment, which is parallel to the long axis of the cells and continuous with the stress fibers in adjacent cells [32]. ECs are exposed to shear flow under physiological conditions. The appropriate laminar flow with high shear stress enhances expression of certain genes and proteins, which stabilize ECs and protect against atherosclerosis [39]. The signaling induced by shear stress and R-Ras signaling may share a common molecular mechanism to maintain vascular homeostasis via actin cytoskeleton organization.

Among many Ras-like small GTPases, R-Ras is, to our best knowledge, the only Ras protein that has been shown to inhibit VEGF signaling and suppresses angiogenic phenotype of ECs. The expression of R-Ras is high in quiescent ECs of mature vessels [12]. In contrast, R-Ras is significantly downregulated in ECs during developmental and pathological vessel formation [12]. This downregulation would allow ECs to fully respond to VEGF and initiate cell migration in order to develop new vessel sprouts as instructed by the angiogenic cue. Nonetheless, ECs must cease migration at the appropriate timing to allow new sprouts to stabilize and form functional vessels. Our findings suggest that R-Ras provides a mechanism to prevent unnecessary or excessive angiogenic response to VEGF. Previously, we found that R-Ras is important for structural and functional maturation of regenerating blood vessels and the normalization of tumor vasculature [11]. Considering this role of R-Ras, our results suggest a potential link between vessel maturation/normalization and the attenuation of the VEGFR2-p38MAPK-HSP27 axis. The normalization of tumor vasculature could enhance chemotherapy by improving drug delivery and penetration [40]. Ralimetinib, a p38MAPK inhibitor, in combination with conventional chemotherapy is currently in clinical trial for treating ovarian cancer patients. It would be interesting to investigate how this p38MAPK inhibition therapy alters the tumor vasculature in human cancer and consequently affects the overall outcome of the combination therapy.

Conclusion

Based on our results, we conclude that R-Ras inhibits VEGF-induced membrane protrusion and migration via downregulation of the p38MAPK-HSP27 axis of VEGF signaling. Our study postulates how R-Ras contributes to quiescence of ECs and vessel stabilization through inhibition of overstimulation by VEGF.

Acknowledgement

Histological preparations and imaging were done at the Histology and Imaging Core Facilities of Sanford-Burnham-Prebys Medical Discovery Institute at Lake Nona. This work was supported by the National Cancer Institute (grant CA125255), the Florida Department of Health Bankhead-Cole Cancer Research Program 4BB17, the National Science Foundation CBET-1403535 and the American Heart Association 15POST25700319.

Disclosure Statement

There are no conflicts of interest.

References

- Holmes K, Roberts OL, Thomas AM, Cross MJ: Vascular endothelial growth factor receptor-2: Structure, function, intracellular signaling and therapeutic inhibition. *Cell Signal* 2007;19:2003–2012.
- Ferrara N: Vascular endothelial growth factor. *Arterioscler Thromb Vasc Biol* 2009;29:789–791.
- Gavard J, Gutkind JS: VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VEGFR2. *Nat Cell Biol* 2006;8:1223–1234.
- Darland DC, D'Amore PA: Blood vessel maturation: vascular development comes of age. *J Clin Invest* 1999;103:157–158.
- Carmeliet P, Jain RK: Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. *Nat Rev Drug Discov* 2011;10:417–427.
- Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. *Science* 2005;307:58–62.
- Behl T, Kotwani A: Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy. *Pharmacol Res* 2015;99:137–148.
- Said SS, Pickering JG, Mequanint K: Advances in growth factor delivery for therapeutic angiogenesis. *J Vasc Res* 2013;50:35–51.
- Mughal NA, Russell DA, Ponnambalam S, Homer-Vanniasinkam S: Gene therapy in the treatment of peripheral arterial disease. *Br J Surg* 2012;99:6–15.
- Giacca M, Zacchigna S: VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond. *Gene Ther* 2012;19:622–629.
- Sawada J, Urakami T, Li F, Urakami A, Zhu W, Fukuda M, Li DY, Ruoslahti E, Komatsu M: Small GTPase R-Ras regulates integrity and functionality of tumor blood vessels. *Cancer Cell* 2012;22:235–249.
- Komatsu M, Ruoslahti E: R-Ras is a global regulator of vascular regeneration that suppresses intimal hyperplasia and tumor angiogenesis. *Nature Medicine* 2005;11:1346–1350.
- Marte BM, Rodriguez-Viciana P, Wennstrom S, Warne PH, Downward J: R-Ras can activate the phosphoinositide 3-kinase but not the map kinase arm of the ras effector pathways. *Curr Biol* 1997;7:63–70.
- Lowe DG, Goeddel DV: Heterologous expression and characterization of the human r-ras gene product. *Molecular and Cellular Biology* 1987;7:2845–2856.
- Zhang Z, Vuori K, Wang H, Reed JC, Ruoslahti E: Integrin activation by r-ras. *Cell* 1996;85:61–69.
- Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, Jonckx B, Tian YM, Llanahan AA, Pollard P, Ruiz de Almodovar C, De Smet F, Vinckier S, Aragones J, Debackere K, Luttun A, Wyns S, Jordan B, Pisacane A, Gallez B, Lampugnani MG, Dejana E, Simons M, Ratcliffe P, Maxwell P, Carmeliet P: Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. *Cell* 2009;136:839–851.
- Meadows KN, Bryant P, Pumiglia K: Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. *J Biol Chem* 2001;276:49289–49298.
- Meadows KN, Bryant P, Vincent PA, Pumiglia KM: Activated Ras induces a proangiogenic phenotype in primary endothelial cells. *Oncogene* 2004;23:192–200.
- Lakshminathan S, Sobczak M, Chun C, Henschel A, Dargatz J, Ramchandran R, Chrzanoska-Wodnicka M: Rap1 promotes VEGFR2 activation and angiogenesis by a mechanism involving integrin $\alpha v \beta_3$. *Blood* 2011;118:2015–2026.
- Westenskow PD, Kurihara T, Aguilar E, Schepke EL, Moreno SK, Wittgrove C, Marchetti V, Michael IP, Anand S, Nagy A, Cheresch D, Friedlander M: Ras pathway inhibition prevents neovascularization by repressing endothelial cell sprouting. *J Clin Invest* 2013;123:4900–4908.
- Sawada J, Li F, Komatsu M: R-Ras protein inhibits autophosphorylation of vascular endothelial growth factor receptor 2 in endothelial cells and suppresses receptor activation in tumor vasculature. *J Biol Chem* 2015;290:8133–8145.
- Katsogiannou M, Andrieu C, Rocchi P: Heat shock protein 27 phosphorylation state is associated with cancer progression. *Front Genet* 2014;5:346.
- Kobayashi M, Nishita M, Mishima T, Ohashi K, Mizuno K: MAPKAPK-2-mediated LIM-kinase activation is critical for VEGF-induced actin remodeling and cell migration. *EMBO J* 2006;25:713–726.
- Rousseau S, Houle F, Huot J: Integrating the VEGF signals leading to actin-based motility in vascular endothelial cells. *Trends Cardiovasc Med* 2000;10:321–327.
- Rousseau S, Houle F, Kotanides H, Witte L, Waltenberger J, Landry J, Huot J: Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. *J Biol Chem* 2000;275:10661–10672.
- Huot J, Houle F, Spitz DR, Landry J: Hsp27 phosphorylation-mediated resistance against actin fragmentation and cell death induced by oxidative stress. *Cancer Res* 1996;56:273–279.
- Guay J, Lambert H, Gingras-Breton G, Lavoie JN, Huot J, Landry J: Regulation of actin filament dynamics by p38 MAP kinase-mediated phosphorylation of heat shock protein 27. *J Cell Sci* 1997;110(Pt 3):357–368.
- Rousseau S, Houle F, Landry J, Huot J: p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. *Oncogene* 1997;15:2169–2177.

- 29 Piotrowicz RS, Hickey E, Levin EG: Heat shock protein 27 kDa expression and phosphorylation regulates endothelial cell migration. *FASEB J* 1998;12:1481–1490.
- 30 Huot J, Houle F, Marceau F, Landry J: Oxidative stress-induced actin reorganization mediated by the p38 mitogen-activated protein kinase/heat shock protein 27 pathway in vascular endothelial cells. *Circ Res* 1997;80:383–392.
- 31 Lamalice L, Le Boeuf F, Huot J: Endothelial cell migration during angiogenesis. *Circ Res* 2007;100:782–794.
- 32 Noria S, Xu F, McCue S, Jones M, Gotlieb AI, Langille BL: Assembly and reorientation of stress fibers drives morphological changes to endothelial cells exposed to shear stress. *Am J Pathol* 2004;164:1211–1223.
- 33 Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C: VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. *J Cell Biol* 2003;161:1163–1177.
- 34 McMullen ME, Bryant PW, Glembotski CC, Vincent PA, Pumiglia KM: Activation of p38 has opposing effects on the proliferation and migration of endothelial cells. *J Biol Chem* 2005;280:20995–21003.
- 35 Zheng C, Lin Z, Zhao ZJ, Yang Y, Niu H, Shen X: MAPK-activated protein kinase-2 (MK2)-mediated formation and phosphorylation-regulated dissociation of the signal complex consisting of p38, MK2, Akt, and Hsp27. *J Biol Chem* 2006;281:37215–37226.
- 36 Cote MC, Lavoie JR, Houle F, Poirier A, Rousseau S, Huot J: Regulation of vascular endothelial growth factor-induced endothelial cell migration by LIM kinase 1-mediated phosphorylation of annexin 1. *J Biol Chem* 2010;285:8013–8021.
- 37 Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR, Lee JC: SB 203580 is a specific inhibitor of a map kinase homologue which is stimulated by cellular stresses and interleukin-1. *FEBS Lett* 1995;364:229–233.
- 38 Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA: Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. *Oncogene* 2000;19:5606–5613.
- 39 Chiu JJ, Chien S: Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. *Physiol Rev* 2011;91:327–387.
- 40 Jain RK: Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. *Cancer Cell* 2014;26:605–622.